New drug offers hope for breast cancer patients suffering from hot flashes
NCT ID NCT06917313
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called fezolinetant to see if it can reduce hot flashes in women who have had breast cancer and are taking hormone therapy. About 92 women will be randomly assigned to receive either fezolinetant or a placebo daily for 12 weeks. The main goal is to measure how much the frequency of hot flashes decreases.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER EARLY STAGE BREAST CANCER (STAGE 1-3) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Ohio State University Comprehensive Cancer Center
NOT_YET_RECRUITINGColumbus, Ohio, 43201, United States
-
Yale University
RECRUITINGNew Haven, Connecticut, 06511, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Exercise during chemo: a new weapon to preserve strength?
- Could a smartphone program ease Chemo's emotional toll?
- Could fewer heart tests be safer for breast cancer patients?
- New study aims to predict who will respond to breast cancer therapy
- Blood test could revolutionize breast cancer monitoring
- Tech trio aims to help breast cancer survivors remember daily pills